



Collaboration. Acceleration. Results.

**The Myelin Repair Foundation to Present at 11TH Annual BIO Investor Forum
BIO Investor Forum to be held October 9-10 in San Francisco, Calif.**

San Francisco, CA—October 5, 2012 –The [Myelin Repair Foundation \(MRF\)](#) announced that [Dr. Jay Tung](#), Vice President of Drug Discovery will be presenting at the [11th Annual BIO Investor Forum](#) on October 9 at 10:15 am PT in the Marina Room at the Palace Hotel in San Francisco, Calif. Dr. Tung will be presenting on the Myelin Repair Foundation’s unique approach to optimize and accelerate the development and delivery of new therapeutics to the market.

Hosted by the Biotechnology Industry Organization (BIO), the 11TH Annual BIO Investor Forum features leading private and emerging public companies. The meeting will take place October 9-10 at the Palace Hotel in San Francisco, Calif.

“With non-profit organizations playing a bigger role in the industry, the Myelin Repair Foundation is defining a new role to coordinate the overall effort across the entire therapeutic development continuum to address unmet patient need,” said Dr. Jay Tung, Ph.D., Vice President of Drug Discovery at the Myelin Repair Foundation. “At the BIO Investor Forum, we are proud to present our unique approach to therapeutics development in front of an influential audience seeking cutting edge, innovative ideas that will transform the biotech industry.”

Under the leadership of CEO, President and Founder Scott Johnson, the Myelin Repair Foundation has catalyzed myelin repair research and advanced promising myelin repair therapeutics forward into clinical trials for multiple sclerosis. By utilizing the Foundation’s [Accelerated Collaboration Research \(ARC\)™ model](#) designed to shorten the time for new medicines, the MRF is demonstrating for the model to develop a new myelin repair drug for multiple sclerosis by 2019.

About the Myelin Repair Foundation

The Myelin Repair Foundation (MRF) (<http://www.myelinrepair.org>) is a Silicon Valley-based, non-profit research organization focused on accelerating the discovery and development of myelin repair therapeutics for multiple sclerosis. Its Accelerated Research Collaboration™ (ARC™) model is designed to optimize the entire process of medical research, drug development and the delivery of patient treatments.

ABOUT THE BIO INVESTOR FORUM

The 11th Annual BIO Investor Forum is an international investor conference focused on private and emerging public biotech companies. Because our mission is to support industry-wide success, we present a broad and unbiased view of investment opportunities. In addition, the BIO Investor Forum draws business development executives from leading global pharmaceutical and established biotechnology companies.

Contact:

Jennifer Chang

Myelin Repair Foundation

(408) 871-2410

jchang@myelinrepair.org

###